ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter Infection

This study has been completed.

Sponsored by: Poitiers University Hospital
Information provided by: Poitiers University Hospital
ClinicalTrials.gov Identifier: NCT00259350
  Purpose

The best antiseptic solution for cateheter care remains unknown.High concentration in aquous solution or low concentration in alcoholic solution of chlorhexidine actbetter than povidone iodine in aquous solutions. No study has compare alcoholic formulations of low concentration of chlorhexidine and povidone iodine for skin disinfection prior to insertion of central venous catheters.

To compare the incidence of central venous catheter colonization after skin disinfection with either an alcoholic solution of povidone iodine or a combination of 0.5% chlorhexidine, 0.025% Benzalkonium and 4% benzylic alcohol.

To compare the incidence of catheter related bacteremia in the to study groups. To compare the local and general tolerance of the two antiseptic formulations


Condition Intervention Phase
ICU Patients Requiring a Central Venous Access
Drug: Skin disinfection
Phase IV

ChemIDplus related topics:   Iodine    Cadexomer iodine    Chlorhexidine    Chlorhexidine digluconate    Povidone-iodine    Ethanol    Povidone    Benzalkonium chloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Prevention of Central Venous Catheter Infections : Comparison of the Efficacy of Skin Disinfection With 5% Povidone Iodine in Alcoholic Solution Versus 0.25% Chlorhexidine, 0.025 Benzalkonium and 4% Benzylic Alcohol

Further study details as provided by Poitiers University Hospital:

Primary Outcome Measures:
  • Prevention of catheter colonization

Secondary Outcome Measures:
  • Prevention of catheter related bacteremia
  • Prevention of a positive culture of the catheter whaterver the threshold
  • Local and general tolerance

Estimated Enrollment:   520
Study Start Date:   May 2004
Estimated Study Completion Date:   April 2006

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients over 18 yeras of age
  • Requiring an internal jugular or sub-clavian central venous catheter for their care during at least 72 h
  • Informed consent signed up

Exclusion Criteria:

  • Bacteriemic infection not under control
  • extensive cutaneous infection
  • Women with childbearing potential
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00259350

Locations
France, Vienne
University hospital    
      Poitiers, Vienne, France, 86021

Sponsors and Collaborators
Poitiers University Hospital

Investigators
Study Chair:     Olivier MIMOZ, MD, PhD     University Hospital of Poitiers, france    
  More Information


Publications indexed to this study:

Study ID Numbers:   Anticath
First Received:   November 27, 2005
Last Updated:   December 5, 2006
ClinicalTrials.gov Identifier:   NCT00259350
Health Authority:   France: Afssaps - French Health Products Safety Agency

Keywords provided by Poitiers University Hospital:
Central venous catheter  
Skin disinfection  
Antisepsis  
Nosocomial infection  
Catheter infection  

Study placed in the following topic categories:
Chlorhexidine
Chlorhexidine gluconate
Povidone
Iodine
Povidone-Iodine
Ethanol

Additional relevant MeSH terms:
Anti-Infective Agents
Anti-Infective Agents, Local
Disinfectants
Therapeutic Uses
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 06, 2008




Links to all studies - primarily for crawlers